ArticleCureus2026
Mechanobiological Stimulation With Nanoencapsulated Recombinant Growth Factors Combined With Subcision for the Treatment of Complex Post-traumatic Atrophic Facial Scars: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-traumatic atrophic scars represent a complex therapeutic challenge whose pathophysiology involves three concurrent structural deficits: reticular dermis degradation, formation of vertical fibrous tracts that anchor the skin to deep planes, and subcutaneous lipoatrophy. We present a three-session multimodal protocol at two-week intervals, applied to a 53-year-old female patient with atrophic scars of the right hemiface secondary to a motor vehicle accident, refractory to prior reconstructive surgery, autologous fat transfer, and 10 sessions of fractional CO₂ laser. The protocol integrated tumescent hydrodissection, subcision with a 22G blunt cannula, controlled adipose tunneling to activate the stromal vascular fraction (SVF) in situ, and immediate transepidermal and retrograde delivery of nanoencapsulated recombinant human growth factors (rh-GF). Objective assessment using the Vancouver Scar Scale (VSS) demonstrated a 50% reduction in total score (from 6 to 3 points out of 14), with the greatest gains in pliability (4 → 2) and height (1 → 0), maintained at six months of follow-up. The patient spontaneously reported reduced sensation of pressure and facial stiffness, as well as improvement in her self-esteem and perceived quality of life. This single-case report - with the limitations inherent to this study design - provides preliminary evidence that justifies the development of prospective controlled studies to evaluate the integration of mechanotransduction, adipose regeneration, and molecular signaling in complex scar defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.